Pralatrexate experience in peripheral T-cell lymphoma: A multicenter retrospective study from Turkey

Simple item page
dc.contributor.authorDal M.S.
dc.contributor.authorMerdin A.
dc.contributor.authorErkurt M.A.
dc.contributor.authorEkinci Ö.
dc.contributor.authorAlbayrak M.
dc.contributor.authorHacıoglu S.K.
dc.contributor.authorKaya A.
dc.contributor.authorDogu M.H.
dc.contributor.authorHindilerden F.
dc.contributor.authorSarici A.
dc.contributor.authorMerter M.
dc.contributor.authorAras M.R.
dc.contributor.authorCaglıyan G.A.
dc.contributor.authorCakar M.K.
dc.contributor.authorAydogdu I.
dc.contributor.authorKuku I.
dc.contributor.authorKorkmaz S.
dc.contributor.authorUlas T.
dc.contributor.authorEser B.
dc.contributor.authorAltuntas F.
dc.date.accessioned2024-07-22T08:05:54Z
dc.date.available2024-07-22T08:05:54Z
dc.date.issued2021
dc.description.abstractPurpose: Pralatrexate is a new generation antifolate treatment agent used for the treatment of relapsed or refractory peripheral T-cell lymphomas. This study aims to determine the general characteristics of the patients receiving pralatrexate therapy in Turkey, contributing to the literature on the effectiveness of pralatrexate therapy in peripheral T-cell lymphomas by determining the response levels of such patients to the therapy. The study also attempts to clinically examine the major side effects observed in patients during treatment with pralatrexate. Methods: The study included patients with peripheral T-cell lymphoma followed up in the hematology units of several hospitals in Turkey. Overall, 20 patients aged 18 and over were included in the study. Results: The median age at the time of diagnosis was 58.5 years. PTCL-NOS (Peripheral T-cell lymphoma, not otherwise specified) subtype was in 40% of patients, making the PTCL-NOS the most common subtype in the study. In general, most patients were diagnosed with disease at an advanced stage. Pralatrexate therapy was given to the patients at a median treatment line of 3.5. Pralatrexate dose reduction was required in only 3 patients (15%). Response to pralatrexate therapy with partial remission (PR) and above was observed in 11 (55%) of the patients. Conclusion: Pralatrexate seemed to be a promising novel treatment in relapsed refractory PTCL patients. However, patients receiving pralatrexate should be followed up carefully for skin reactions, mucosal side effects, thrombocytopenia and neutropenia. © 2021 Zerbinis Publications. All rights reserved.
dc.identifier.issn11070625
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13281
dc.language.isoEnglish
dc.publisherZerbinis Publications
dc.subjectAminopterin
dc.subjectFemale
dc.subjectHumans
dc.subjectLymphoma, T-Cell, Peripheral
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectRetrospective Studies
dc.subjectTreatment Outcome
dc.subjectTurkey
dc.subjectpralatrexate
dc.subject10-propargyl-10-deazaaminopterin
dc.subjectaminopterin
dc.subjectadult
dc.subjectadvanced cancer
dc.subjectangioimmunoblastic T cell lymphoma
dc.subjectArticle
dc.subjectautologous stem cell transplantation
dc.subjectcancer chemotherapy
dc.subjectcancer regression
dc.subjectcancer staging
dc.subjectcancer survival
dc.subjectclinical article
dc.subjectconstipation
dc.subjectcutaneous T cell lymphoma
dc.subjectdemography
dc.subjectdiarrhea
dc.subjectdrug dose reduction
dc.subjectdrug safety
dc.subjectfemale
dc.subjectfollow up
dc.subjecthepatosplenic gamma delta T cell lymphoma
dc.subjecthospital
dc.subjecthuman
dc.subjectmale
dc.subjectmiddle aged
dc.subjectmultiple cycle treatment
dc.subjectmycosis fungoides
dc.subjectnausea
dc.subjectneutropenia
dc.subjectoverall survival
dc.subjectperipheral T cell lymphoma
dc.subjectrash
dc.subjectretrospective study
dc.subjectSezary syndrome
dc.subjectstomatitis
dc.subjectthrombocytopenia
dc.subjectTurkey (republic)
dc.subjectclinical trial
dc.subjectmulticenter study
dc.subjectperipheral T cell lymphoma
dc.subjecttreatment outcome
dc.subjectturkey (bird)
dc.titlePralatrexate experience in peripheral T-cell lymphoma: A multicenter retrospective study from Turkey
dc.typeArticle

Files

Collections

Scopus Koleksiyonu